ATH434, Alterity Therapeutics’ experimental oral therapy, prevented a loss in the sense of smell — an early and common symptom of Parkinson’s disease — in a mouse model, and helped to preserve nerve cells and restore motor skills in older animals, a study showed. These findings add to those…
News
The American Parkinson Disease Association (APDA) will host a free, two-day virtual conference for people with Parkinson’s disease and their caregivers on February 15–16. The program is scheduled to run from 12 p.m. to 3:30 p.m. EST each day. “The APDA Virtual Parkinson’s Conference will include an…
The activity of multiple genes in the brain varies according to sex among people with Parkinson’s disease, a new study reports. These differences may contribute to discrepancies in how Parkinson’s tends to affect men and women. “While males have a higher age-adjusted disease incidence and are more frequently affected…
High-frequency stimulation of both the brain’s primary motor cortex (M1) and its dorsolateral prefrontal cortex (DLPFC) — two regions with altered activity in Parkinson’s disease — may be the optimal use of transcranial magnetic stimulation (TMS) in easing Parkinson’s motor symptoms, a meta-analysis study reported. In analyzing data from…
Researchers have developed a video-based algorithm to predict the severity of tremor in Parkinson’s disease patients based on the criteria of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). The new algorithm was found to identify tremors, both resting and postural, with high accuracy — ranging from…
Suppressing the production of an enzyme called nitric oxide synthase 2 (NOS2) led to reductions in alpha-synuclein-related abnormalities and neuroinflammation in a mouse model of Parkinson’s disease, a new study reports. “Our data indicate that NOS2 may be a therapeutic target for modulating [Parkinson’s disease] in the brain,” the…
The U.S. Food and Drug Administration (FDA) has lifted its full clinical hold on IkT-148009, Inhibikase Therapeutics’ investigational oral therapy for Parkinson’s disease. The agency had placed a hold on all clinical trials of IkT-158009 in December, just a few months after Inhibikase had begun dosing Parkinson’s patients in a …
Annovis Bio anticipates an interim data analysis from a Phase 3 trial of its therapeutic candidate buntanetap in people with early-stage Parkinson’s disease will be possible by mid-year, based on current trial enrollment. By then, there will likely be enough patients who’ll have received at least two months…
The PD GENEration study is halfway to its goal of providing free genetic testing and counseling to 15,000 people with Parkinson’s disease, with 7,500 patients included in the effort to date. “Ensuring that the entire Parkinson’s community — including the 90,000 individuals expected to receive a PD [Parkinson’s…
A cognitive-motor training program featuring a video game platform that promotes exercise is feasible for people with Parkinson’s disease to use, a new study demonstrates. Patients using the program along with standard rehabilitation showed comparable and greater motor and cognitive improvements relative to those on standard rehabilitation alone. These preliminary…
Recent Posts
- Blocking 2 proteins could slow Parkinson’s progression: Study
- How to minimize stress while traveling with Parkinson’s disease
- New PET tracer helps scientists ‘see’ Parkinson’s toxic protein clumps
- Tech duo to advance brain-penetrating drugs for CNS disorders
- New trial offers extended buntanetap access for people with Parkinson’s